Braveheart Bio Presents HCM Therapeutic Data at AHA Scientific Sessions
What happened
Carlos del Rio presented research at the American Heart Association Scientific Sessions 2026. The presentations included 52-week extension results for BHB-1893 in obstructive hypertrophic cardiomyopathy and an oral abstract on the drug's ability to improve diastolic function in non-obstructive hypertrophic cardiomyopathy. The presentations were announced by Braveheart Bio, Inc. in October 2026.
From manilatimes.net
Why it matters
The presentation of clinical trial results for BHB-1893, a next-generation cardiac myosin inhibitor, provides information on the long-term efficacy and safety of the therapeutic. This research is relevant to the field of cardiovascular disease treatment.
The American Heart Association hosted the EPI|Lifestyle Scientific Sessions 2026 in Boston.
From manilatimes.net
Who's involved
- Carlos del RioPresented research findings on cardiac therapeutics at the AHA Scientific Sessions.
- American Heart AssociationHosted the Scientific Sessions where the clinical research data was presented.
Keep exploring
The entities involved
-
Carlos del Rio
Mexican-American physician
Nothing else this week.
-
American Heart Association
US nonprofit funding cardiovascular medical research, educating consumers on healthy living, and fostering cardiac care